PTK2 and prostate carcinoma: Corroborating this finding, another study demonstrated that FAK inhibition by co-administration of defactinib and docetaxel reduces the viability of docetaxel-sensitive and resistant PC-3 and DU145 prostate cancer cells, inhibits the growth of PC-3 xenografts, and induces apoptosis in patient-derived prostate tumor explants [150].